Minocycline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Minocycline
- Minocycline: From Bacterial Infections and Acne to Punctate Epithelial Keratoconjunctivitis
Minocycline: From Bacterial Infections and Acne to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Minocycline is a tetracycline-class antibiotic, originally used for bacterial infections such as urinary tract infection, bronchitis, acne, periodontitis, and gonorrhea. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis, but no clinical trials or publications currently support this specific prediction, so it rests on model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Urinary tract infection, bronchitis, acne, anthrax infection, periodontitis, gonorrhea, pharyngitis and other bacterial infections (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Based on known information, minocycline is a tetracycline-class antibiotic whose efficacy in bacterial infections and acne is established. Mechanistically, it may be applicable to inflammatory conditions of the ocular surface.
A plausible link is the anti-inflammatory and matrix metalloproteinase (MMP)-inhibiting activity of tetracyclines on the ocular surface. This class is used in meibomian gland dysfunction and blepharitis. This reasoning is inferred and is not supported by any trial or publication compiled for this report.
Other predictions in the top 10 (for example exposure keratitis, neurotrophic keratopathy, chronic rhinosinusitis) follow similar speculative reasoning. Otitis externa is the only one with indirect literature, and none of it is controlled clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for punctate epithelial keratoconjunctivitis.
Literature Evidence
Currently no related literature available for punctate epithelial keratoconjunctivitis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15432P | BORYMYCIN CAPSULE 50MG | Capsule | Not stated in the data |
| SIN10160P | AA PHARMA MINOCYCLINE CAPSULE 50 mg | Capsule | Not stated in the data |
| SIN10266P | BORYMYCIN CAPSULE 100 mg | Capsule | Not stated in the data |
| SIN10155P | AA PHARMA MINOCYCLINE CAPSULE 100 mg | Capsule | Not stated in the data |
| SIN15172P | PERIOCLINE PERIODONTAL OINTMENT 2% W/W | Ointment | Not stated in the data |
All five registrations are valid single-ingredient products. Four are oral capsules, and one is a periodontal ointment. No ophthalmic formulation is registered, so a new route of administration would likely be needed for an eye indication.
Safety Considerations
- Contraindication-related conditions (from the knowledge graph, not package insert text): kidney disease, liver disease, gallbladder disease, Clostridium difficile colitis, perinatal necrotizing enterocolitis, pseudotumor cerebri, intracranial hypertension, pyoureter, dyskinesia of esophagus.
- Drug Interactions: 100 interactions were identified. Main ones include:
- Major: isotretinoin and acitretin (retinoids; the risk of raised intracranial pressure is a known concern with tetracyclines).
- Moderate: ethinylestradiol, amoxicillin, ampicillin, aminolevulinic acid (topical), calcium phosphate, calcium acetate, sodium citrate, bismuth subcitrate potassium, balsalazide, cannabidiol, brentuximab vedotin, and asparaginase products.
- Minor: acetazolamide, hydrochlorothiazide, amiloride, bumetanide.
- Other signals from the prediction review: Minocycline has been associated with drug-induced vasculitis, so the predicted "postinfectious vasculitis" indication raises a safety concern rather than supporting use. A 2023 in vitro study also suggests a cytotoxicity signal for tetracyclines in tympanic membrane fibroblasts, relevant to any topical otic use.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a high model score (99.63%) and a plausible but unverified anti-inflammatory mechanism. No trials or publications address punctate epithelial keratoconjunctivitis, and no ophthalmic minocycline product is registered in Singapore. The evidence level is L5, so there is not enough basis to advance.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Health Sciences Authority (HSA), which are required for safety screening
- Detailed mechanism of action data (for example from DrugBank)
- Literature search for tetracycline or minocycline in ocular surface inflammation, and any preclinical data in keratoconjunctivitis models
- Assessment of route compatibility, since an ophthalmic or topical ocular formulation would be needed and none is currently registered
- Review of the alternative predictions (for example chronic rhinosinusitis, otitis externa) if the ocular prediction is not pursued, noting that all currently remain at L4–L5 evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.